Monster Beverage Rises After Firms Start Shares With Buy Ratings

NEW YORK ( TheStreet) -- Shares of energy drink maker Monster Beverage ( MNST)are climbing after two research firms recommended buying the stock in initiation reports earlier today. 


WHAT'S NEW: Monster could benefit from several factors, including accelerating energy beverage trends and strong overseas sales opportunities that are being undervalued by the market, according to Wells Fargo, which initiated coverage of the stock with an Outperform rating. Additionally, the beverage maker has multiple upcoming new products that should boost its revenue and an attractive valuation, Wells believes. The firm set a $79-$81 price target range on the stock. Similarly, research firm BTIG initiated coverage of Monster with a Buy rating, saying the market is overly pessimistic about the outlook of the energy drink sector as well as the company's overseas sales. Additionally, the firm believes that the stock is reflecting too much concern about increased regulation of energy drinks. BTIG sees very little chance that regulators will take any action beyond placing warning labels on energy drinks. It set a $90 price target on the shares.

WHAT'S NOTABLE: On June 3, BMO Capital wrote that it had more confidence in Monster's ability to maintain its growth momentum in the U.S. and strengthen its international financial results. The firm reiterated a $77 price target and Outperform rating on the stock at that time.

PRICE ACTION: In early afternoon trading, Monster climbed about 1.5% to $72.40.

 

Reporting by Larry Ramer.

The Fly provides comprehensive coverage of stock news and Street research and delivers it in real-time. The Fly breaks market-moving news and explains sudden stock movements in a rapid-fire, short-form story format. Follow @theflynews on Twitter. For a free trial, click here.

More from Investing

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat